MedPath

Fennec Pharmaceuticals

Ownership
-
Employees
29
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

1

FDA:1

Drug Approvals

PEDMARK

Approval Date
Sep 30, 2022
FDA

Clinical Trials

No trials found

News

NICE Recommends Pedmarqsi as First NHS Treatment for Cisplatin-Induced Hearing Loss in Children

The National Institute for Health and Care Excellence (NICE) has recommended Pedmarqsi for preventing cisplatin-induced hearing loss in young patients aged 1 month to 17 years.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.